Evidence map›Paper›PMID 24964950›Full record

ArticleExpert review of vaccines2014

The value of HIV protective epitope research for informed vaccine design against diverse viral pathogens.

Victor G Kramer, Siddappa N Byrareddy

Abstract readEditorial
In one paragraph

Article in Expert review of vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Victor G KramerMcGill AIDS Centre, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada.
Siddappa N Byrareddy

Funding

Escape From Broadly Neutralizing MAbs by Genetically-Linked Early & Late HIV EnvsR21AI098581 · NIAID · EMORY UNIVERSITY · PI BYRAREDDY, SIDDAPPA N · 2012 to 2013
$484k
Transmitted/Founder SHIV macaque modelR21AI114415 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BYRAREDDY, SIDDAPPA N · 2015 to 2016
$414k
NIAID NIH HHS R21 AI098581NIAID NIH HHS R21 AI114415
6 · The paper itself

Abstract

The success of vaccine regimens against viral pathogens hinges on the elicitation of protective responses. Hypervariable pathogens such as HIV avoid neutralization by masking protective epitopes with more immunogenic decoys. The identification of protective, conserved epitopes is crucial for future vaccine candidate design. The strategies employed for identification of HIV protective epitopes will also aid towards rational vaccine design for other viral pathogens.

Indexed as

Drug DiscoveryEpitopesHumansViral VaccinesVirus DiseasesEpitopesViral VaccinesepitopeglycanH1N1HIVvaccine

Identifiers

PMID24964950
PMCPMC4128321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.